Previous 10 | Next 10 |
Galapagos' (GLPG) collaboration partner Gilead Sciences (GILD) has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency ((PMDA)) for approval of filgotinib for an additional indication to treat moderately to severely active ulcerative colitis ((UC)). This late...
Application is based on Phase 2b/3 SELECTION study data with patients with moderately to severely active ulcerative colitis Mechelen, Belgium ; 23 April 2021 ; 06.01 CET ; – Galapagos NV (Euronext & Nasdaq: GLPG) today report ...
Gilead's shares have come down a lot over the last year, once euphoria around Veklury passed. Gilead is well-positioned in HIV and several other markets. The company combines a low valuation with attractive dividend growth properties. For further details see: Gilead Scie...
Galapagos (GLPG) and Gilead (GILD) announces amendment to the share subscription agreement closed in 2019, extending the full lock-up of Gilead’s current shareholding in Galapagos to 2024.Previously, there was a full lock-up of 2 years, followed by a 3-year period during which the...
Mechelen, Belgium; 08 April 2021; 22.01 CET; Galapagos (Euronext & Nasdaq; GLPG) announced today that Gilead and Galapagos signed an amendment to the share subscription agreement closed in 2019, extending the full lock-up of Gilead’s current shareholding in Galapagos to 2...
Mechelen, Belgium; 25 March 2021; 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2020. The annual report for the financial year 2020, including a review of figures and performance, is availa...
Galapagos (GLPG) promotes Bart Filius to President and COO.Bart Filius joined in 2014 as CFO and subsequently took on the responsibility as COO in 2017. Going forward, CEO Onno van de Stolpe will maintain oversight of the research and development activities, while ...
Mechelen, Belgium; 24 March 2021; 21.01 CET; Galapagos (Euronext & Nasdag; GLPG) announced today that its Supervisory Board has promoted Bart Filius to President and Chief Operating Officer (COO). Going forward, CEO Onno van de Stolpe will maintain oversight of the research and develo...
Galapagos received a CRL on filgotinib in rheumatoid arthritis. Latest data seems to address the issues raised by the FDA. The company is trading at negative enterprise value. For further details see: Galapagos May Finally Get Around Its CRL Situation
Galapagos (GLPG) announces interim results from MANTA and MANTA-RAy, two ongoing safety studies investigating the effect of Jyseleca (filgotinib) on sperm parameters in males with inflammatory bowel disease ((MANTA)) or rheumatic conditions (MANTA-RAy). In total, 248 patients were random...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...